Hepatic Fibrosis Assessed Using Fibrosis-4 Index Is Predictive of All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease

References

• SmithMC, WrobelJP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888. doi:10.2147/COPD.S4962125210449
   PubMed Web of Science ®Google Scholar
• ViglinoD, Jullian-DesayesI, MinovesM, et al. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017;49(6):1601923. doi:10.1183/13993003.01923-201628596431
   PubMed Web of Science ®Google Scholar
• KwakMS, KimE, JangEJ, LeeCH. The association of non-alcoholic fatty liver disease with lung function: a survey design analysis using propensity score. Respirology. 2018;23(1):82–88. doi:10.1111/resp.1312728749019
   PubMed Web of Science ®Google Scholar
• LeeCH, ChoiSH, ChungGE, ParkB, KwakMS. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int. 2018;38(11):2091–2100. doi:10.1111/liv.1386029660233
   PubMed Web of Science ®Google Scholar
• MoonSW, KimSY, JungJY, et al. Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population, Korea National Health and Nutrition Examination Survey, 2007–2010. Int J Chron Obstruct Pulmon Dis. 2018;13:2603–2611. doi:10.2147/COPD.S16690230214178
   PubMed Web of Science ®Google Scholar
• MantovaniA, LonardoA, VincoG, et al. Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis. Diabetes Metab. 2019;45(6):536–544. doi:10.1016/j.diabet.2019.04.00831067493
   PubMed Web of Science ®Google Scholar
• SongJU, JangY, LimSY, et al. Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: a longitudinal cohort study. PLoS One. 2019;14(1):e0208736. doi:10.1371/journal.pone.020873630673698
   PubMed Web of Science ®Google Scholar
• SterlingRK, LissenE, ClumeckN, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.2117816729309
   PubMed Web of Science ®Google Scholar
• KimBK, KimDY, ParkJY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546–553. doi:10.1111/j.1478-3231.2009.02192.x20074094
   PubMed Web of Science ®Google Scholar
• SuhB, ParkS, ShinDW, et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology. 2015;61(4):1261–1268. doi:10.1002/hep.2765425502481
   PubMed Web of Science ®Google Scholar
• ChonYE, JungES, ParkJY, et al. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol. 2012;46(6):518–525. doi:10.1097/MCG.0b013e31825079f122688146
   PubMed Web of Science ®Google Scholar
• ChunHS, KimBK, ParkJY, et al. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2019. doi:10.1097/meg.0000000000001512
   PubMed Web of Science ®Google Scholar
• IwasakiY, TomiyamaH, ShiinaK, et al. Liver stiffness and arterial stiffness/abnormal central hemodynamics in the early stage of heart failure. Int J Cardiol Heart Vasc. 2018;20:32–37. doi:10.1016/j.ijcha.2018.07.00130094333
   PubMed Web of Science ®Google Scholar
• JeongSM, KwonH, ParkS, et al. Favorable impact of non-alcoholic fatty liver disease on the cerebral white matter hyperintensity in a neurologically healthy population. Eur J Neurol. 2019;26(12):1471–1478. doi:10.1111/ene.1402931233672
   PubMed Web of Science ®Google Scholar
• MiyataM, KurodaM, UnakamiM, TasakiK, MigitaK, OhiraH. Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. Mod Rheumatol. 2018. doi:10.1080/14397595.2018.1542962.1-7
   Web of Science ®Google Scholar
• Up KimS, KimBK, ParkJY, et al. Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: a retrospective monocentric study. Mod Rheumatol. 2018. doi:10.1080/14397595.2018.1558760.1-16
   Web of Science ®Google Scholar
• ParkHJ, ParkJY, JungSM, SongJJ, ParkYB, LeeSW. Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. BMC Gastroenterol. 2019;19(1):90. doi:10.1186/s12876-019-1007-z31196158
   PubMed Web of Science ®Google Scholar
• DivoM, CoteC, de TorresJP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC22561964
   PubMed Web of Science ®Google Scholar
• FabbriLM, LuppiF, BegheB, RabeKF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–212. doi:10.1183/09031936.0011430718166598
   PubMed Web of Science ®Google Scholar
• LonardoA, NascimbeniF, Ponz de LeonM. Nonalcoholic fatty liver disease and COPD, is it time to cross the diaphragm? Eur Respir J. 2017;49(6):1700546. doi:10.1183/13993003.00546-201728596428
   PubMed Web of Science ®Google Scholar
• ViglinoD, PlazanetA, BaillyS, et al. Impact of non-alcoholic fatty liver disease on long-term cardiovascular events and death in chronic obstructive pulmonary disease. Sci Rep. 2018;8(1):16559. doi:10.1038/s41598-018-34988-230410123
   PubMed Web of Science ®Google Scholar
• AnguloP, KleinerDE, Dam-LarsenS, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e310. doi:10.1053/j.gastro.2015.04.04325935633
   PubMed Web of Science ®Google Scholar
• Vallet-PichardA, MalletV, NalpasB, et al. FIB-4, an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–36. doi:10.1002/hep.2166917567829
   PubMed Web of Science ®Google Scholar
• TanniSE, PelegrinoNR, AngeleliAY, CorreaC, GodoyI. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond). 2010;7:29. doi:10.1186/1476-9255-7-2920534161
   PubMed Web of Science ®Google Scholar
• SaitoA, HorieM, NagaseT. TGF-beta signaling in lung health and disease. Int J Mol Sci. 2018;19(8):2460. doi:10.3390/ijms19082460
   PubMed Web of Science ®Google Scholar
• OsawaY, HoshiM, YasudaI, SaibaraT, MoriwakiH, KozawaO. Tumor necrosis factor-alpha promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells. PLoS One. 2013;8(6):e65251. doi:10.1371/journal.pone.006525123755201
   PubMed Web of Science ®Google Scholar
• KrommidasG, KostikasK, PapatheodorouG, et al. Plasma leptin and adiponectin in COPD exacerbations, associations with inflammatory biomarkers. Respir Med. 2010;104(1):40–46. doi:10.1016/j.rmed.2009.08.01219782551
   PubMed Web of Science ®Google Scholar
• FabregatI, Moreno-CaceresJ, SanchezA, et al. TGF-beta signalling and liver disease. FEBS J. 2016;283(12):2219–2232. doi:10.1111/febs.1366526807763
   PubMed Web of Science ®Google Scholar
• ChiangCH, ChuangCH, LiuSL. Transforming growth factor-beta1 and tumor necrosis factor-alpha are associated with clinical severity and airflow limitation of COPD in an additive manner. Lung. 2014;192(1):95–102. doi:10.1007/s00408-013-9520-224153451
   PubMed Web of Science ®Google Scholar
• KangHH, KimIK, LeeHI, et al. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways. Biochem Biophys Res Commun. 2017;490(2):349–355. doi:10.1016/j.bbrc.2017.06.04728623125
   PubMed Web of Science ®Google Scholar
• MesarwiOA, ShinMK, Bevans-FontiS, SchlesingerC, ShawJ, PolotskyVY. Hepatocyte hypoxia inducible factor-1 mediates the development of liver fibrosis in a mouse model of nonalcoholic fatty liver disease. PLoS One. 2016;11(12):e0168572. doi:10.1371/journal.pone.016857228030556
   PubMed Web of Science ®Google Scholar
• KimIH, KisselevaT, BrennerDA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31(3):184–191. doi:10.1097/MOG.000000000000017625850346
   PubMed Web of Science ®Google Scholar
• BussePJ, MathurSK. Age-related changes in immune function, effect on airway inflammation. J Allergy Clin Immunol. 2010;126(4):690–699; quiz 700–691. doi:10.1016/j.jaci.2010.08.011
   Web of Science ®Google Scholar
• ItoK, BarnesPJ. COPD as a disease of accelerated lung aging. Chest. 2009;135(1):173–180. doi:10.1378/chest.08-141919136405
   PubMed Web of Science ®Google Scholar
• Mahrouf-YorgovM, Collin de l’HortetA, CossonC, et al. Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. Rejuvenation Res. 2011;14(4):353–363. doi:10.1089/rej.2010.114621548759
   PubMed Web of Science ®Google Scholar
• SharmaG, HananiaNA, ShimYM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(7):573–580. doi:10.1513/pats.200904-022RM19934352
   PubMedGoogle Scholar